Loading…
Loading…
RAONF (Race Oncology Limited) is no longer actively trading.
This usually means the company was acquired and taken private, delisted from its exchange, or its ticker has been retired. Every price, valuation, dividend, and analyst figure on this page is frozen at the last available trading session and reads as historical reference — not a current-day signal.
RAONF does not currently pay a dividend.
Sell-side consensus EPS, revenue estimates, YoY growth, forward P/E, and per-year analyst coverage — for any covered stock.
Click below to see what's inside, then upgrade to unlock for this and 80,000+ other tickers.
See price against where its own fundamentals say it should trade — the shaded gap is the discount or premium, across five valuation lenses.
Click below to see what's inside, then upgrade to unlock for RAONF and 80,000+ other tickers.
See exactly how RAONF's revenue becomes profit — a Sankey that traces revenue (and its reported segments) through gross profit, operating expenses, and net profit, with the year-over-year change on every line.
The same diagram the Chart Builder draws, right on the Summary tab. Upgrade to unlock it for RAONF and 80,000+ other tickers.
Based in Sydney, Australia, Race Oncology Limited is an Australian precision oncology firm that commenced operations in 2011. The company's primary focus is the development of Zantrene, a potent small molecule designed to inhibit the fatso/fat mass and obesity associated protein (FTO). This therapeutic agent is currently in Phase II/III clinical trials, exploring its potential to treat a range of cancers, including melanoma, clear cell renal cell carcinoma, acute myeloid leukaemia, breast cancer, and ovarian cancer. Race Oncology actively pursues preclinical research through a program with…
The longest government shutdown in US history has forced the federal government to cancel the October 2025 inflation and jobs reports, the Bureau of Labor...
As the Federal Reserve approaches its December rate-setting meeting, analysts at Deutsche Bank see a patchwork of signals making the decision far from...
Race Oncology Ltd (ASX:RAC, OTC:RAONF) has unveiled two new clinical programs for its lead asset RC220, expanding into acute myeloid leukaemia (AML) and...
Pensana PLC (LSE:PRE, OTC:PNSPF) opened Monday's trading sharply higher after it announced a new drilling and metallurgical testwork programme at its...
Race Oncology Ltd made significant progress in the December quarter towards first patient treatment in the Phase 1 trial of RC220 in combination with doxorubicin. The company submitted its ethics and regulatory data package, supporting expected first patient treatment in Q1 CY2025 The quarter also marked continued transformation within Race’s leadership, with the appointment of Dr Megan Baldwin, founder and chief innovation officer of Opthea, as an independent non-executive director, effective January 1, 2025. Dr Baldwin previously served as CEO and managing director of Opthea for a decade, overseeing the progression of its lead asset from preclinical development to global Phase 3 trials. Race also expanded its scientific team with the appointments of Dr Kirsten Curnow and Dr Sumit Shani. “I wish to warmly welcome Megan, Kirsten and Sumit to Race. The ability to attract such outstanding professionals is a testament to the strength of our team and the exciting potential of our work,” RAC CEO Dr Daniel Tillett said. “Like everyone at Race I am looking forward to us treating the first patient with RC220 soon and translating bisantrene’s potential into meaningful outcomes for cancer patients and our shareholders.” Significant progress was made toward initiating a Phase 1 trial of RC220 in combination with doxorubicin for patients with advanced solid tumours. The company submitted the ethics and regulatory package to Bellberry Human Research Ethics Committee (HREC) in early December. In late December, Bellberry HREC requested minor clarifications, which were addressed in mid-January 2025. Pending final ethics and governance approvals, site activation and first patient recruitment are anticipated in Q1 CY2025. Race also announced the discovery of 39 unique FTO protein-binding molecules identified using state-of-the-art NMR fragment screening. The identified compounds are confirmed FTO-binding chemical structures for the development of novel FTO targeting drugs and provide valuable new IP, aiding the development of novel m6A RNA epigenetic pathway drugs. This FTO-targeted drug discovery program was completed in collaboration with the Monash University Fragment Platform (MFP). The company reported cash and cash equivalents of $18.78 million as of 31 December, with over two-thirds of the quarter’s expenditure ($2.1 million) allocated to research and development (R&D) and drug manufacturing. This represents a $4.2 million increase from the previous quarter, driven by a $5.25 million R&D Tax Incentive payment and the conversion of $870,000 in options. Apple Inc (NASDAQ:AAPL, ETR:APC) reported quarterly earnings that topped Wall Street expectations on Thursday, with record revenue of $124.3 billion, despite a decline in iPhone sales in China. The company posted earnings per share (EPS) of $2.40, surpassing analysts' estimates of $2.35. Revenue rose 4% from the previous year, exceeding the $124.12 billion consensus forecast. However, iPhone sales dropped 11.1% in China during the key December quarter, highlighting concerns that Apple’s artificial intelligence push has yet to spark a new upgrade cycle for its flagship product. While the earnings beat provided some relief to investors, the report showed ongoing challenges in one of Apple's most critical markets. Apple shares were flat to slightly positive in after-hours trading.